home / stock / prtg / prtg news

PRTG News and Press, Portage Biotech Inc. From 04/13/22

Stock Information
Company Name: Portage Biotech Inc.
Stock Symbol: PRTG
Market: NASDAQ
Website: portagebiotech.com
Menu
PRTG PRTG Quote PRTG Short PRTG News PRTG Articles PRTG Message Board
Get PRTG Alerts

News, Short Squeeze, Breakout and More Instantly...
PRTG - Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

WESTPORT, Conn., April 13, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer t...
PRTG - Portage Biotech Provides Update on Clinical-Stage and Development Programs

Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued development Company continues to work toward multiple clinical readouts in 2022 Portage is accelerating studies by expanding regions and clinical sites; contin...

PRTG - Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting

WESTPORT, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer tr...

PRTG - Portage Biotech GAAP EPS of -$0.26 beats by $0.01

Portage Biotech press release (NASDAQ:PRTG): Q3 GAAP EPS of -$0.26 beats by $0.01. As of December 31, 2021, the Company had cash and cash equivalents of approximately $25.6 million and total current liabilities of approximately $0.6 million. For further details see: Portage Biotech GAAP...
PRTG - Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

WESTPORT, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer tre...

PRTG - Portage Biotech Announces New Appointments to its Management Team and Board of Directors

Leading biopharma executive Brian Wiley joins as Chief Business Officer Experienced financial consultant Joseph Ciaverella advances to new role as Chief Accounting Officer Jim Mellon, Linda Kozick and Mark Simon will join Portage’s Board of Directors WESTPOR...

PRTG - Portage Biotech Announces Participation in January 2022 Investor Conferences

WESTPORT, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer tre...
PRTG - Portage Biotech reports Q2 results

Portage Biotech (NASDAQ:PRTG): Q2 GAAP EPS of -$0.22. Cash and cash equivalents as of September 30, 2021 were $27.26M Press Release For further details see: Portage Biotech reports Q2 results

PRTG - Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year

Initiated PORT-2 Phase 1/2 IMP-MEL trial in patients with Melanoma & NSCLC Enrollment ongoing in Phase 1 PRECIOUS-01 study of PORT-3 for the treatment of NY-ESO-1 positive solid tumors WESTPORT, Conn., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (...

PRTG - Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference

WESTPORT, Conn., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer tre...
Previous 10 Next 10